Formation of Tau protein aggregates in neurons is a pathological
hallmark of several neurodegenerative diseases, including Alzheimer’s
disease. Fluorescently labeled Tau protein is therefore useful to
study the aggregation of these pathological proteins and to identify
potential therapeutic targets. Conventionally, cysteine residues are
used for labeling Tau proteins; however, the full-length Tau isoform
contains two cysteine residues in the microtubule-binding region,
which are implicated in Tau aggregation by forming intermolecular
disulfide bonds. To prevent the fluorescent label from disturbing
the microtubule binding region, we developed a strategy to fluorescently
label Tau at its C-terminus while leaving cysteine residues unperturbed.
We took advantage of a Sortase A-mediated transpeptidation approach
to bind a short peptide (GGGH6-Alexa647) with
a His-tag and a covalently attached Alexa 647 fluorophore to the C-terminus
of Tau. This reaction relies on the presence of a Sortase recognition
motif (LPXTG), which we attached to the C-terminus of recombinantly
expressed Tau. We demonstrate that C-terminal modification of Tau
protein results in no significant differences between the native and
C-terminally labeled Tau monomer with regard to aggregation kinetics,
secondary structure, and fibril morphology.